Urecholine is a prescription medication marketed under its brand name and contains bethanechol as its sole active ingredient. Bethanechol belongs to the class of muscarinic agonists and is used to treat conditions that affect bladder function. In Hong Kong, Urecholine is classified as a prescription-only product and is supplied as a 25 mg oral pill. It is not an over-the-counter medication and should only be used under the supervision of a qualified healthcare professional.
Bethanechol is a synthetic cholinergic agonist that selectively stimulates muscarinic receptors in the smooth muscle of the urinary bladder and gastrointestinal tract. By binding to these receptors, it:
Because bethanechol does not cross the blood-brain barrier in significant amounts, its effects are primarily peripheral, targeting the bladder without causing central nervous system effects.
Urecholine is approved for the following urological health indications:
These uses are recognized by regulatory agencies in Hong Kong and align with international labeling for bethanechol.
Some clinical studies have explored bethanechol’s effect on gastrointestinal motility disorders, such as chronic constipation. While there is evidence that the drug can stimulate intestinal smooth muscle, this use is not approved by the Hong Kong Department of Health.
Disclaimer: Off-label use of Urecholine requires careful medical supervision and an individualized risk-benefit assessment.
These reactions are usually mild, transient, and resolve with continued therapy or dose adjustment.
If any of these serious symptoms appear, seek immediate medical care.
Patients should disclose all current medications, including over-the-counter products and herbal supplements, to their prescriber.
This article provides educational information about Urecholine and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Clinical studies have examined bethanechol for its pro-kinetic effect on the gastrointestinal tract, but this use is not approved in Hong Kong. Off-label prescribing should only occur after a thorough risk assessment by a physician.
Dizziness can be a sign of hypotension or bradycardia. Sit or lie down, avoid sudden standing, and contact your healthcare provider promptly for evaluation.
Bethanechol passes into breast milk in small amounts. The potential risk to the infant must be weighed against the benefit to the mother; a prescriber may advise discontinuation or close monitoring.
Improved urinary flow, reduced need for catheterization, and lower post-void residual volumes indicate therapeutic effect. If symptoms persist, discuss possible dose adjustment with your doctor.
Urecholine 25 mg tablets commonly bear the imprint “U-25” on one side and the manufacturer’s logo on the other. Verify imprint details with the pharmacy if you have concerns about authenticity.
Alcohol may enhance dizziness or low blood pressure caused by bethanechol. Moderate consumption is advisable, and patients should avoid excessive drinking.
Anticholinergic eye drops have minimal systemic absorption, but they may slightly reduce the overall cholinergic effect. Discuss any concurrent eye medications with your prescriber.
Renal impairment can affect drug clearance. Physicians often start with a lower dose and titrate cautiously, monitoring urinary function and side effects.
Patients often experience a noticeable increase in urine output within a few hours to a day after the first dose, though full therapeutic benefit may develop over several days of consistent dosing.
